SPATA18 and breast cancer: Among the analyzed tumors by using Kaplan-Meier Plotter pan-cancer RNA-seq data, papillary renal cell carcinoma, thyroid carcinoma, endometrial carcinoma, clear cell renal cell carcinoma, HER2 type breast cancer, basal type breast cancer, sarcoma, lung adenocarcinoma, and head and neck squamous cell carcinoma showed lower risk in SPATA18-expressing tumors (HR = 0.22–0.72; Table 3).